Eisai Opens Representative Office in Dubai

Hatfield, England (ots/PRNewswire) -

New EMEA Dubai Office Part of Expansion Plans into Middle East and
Parts of

Africa

PRESS RELEASE NOT INTENDED FOR DUBAI MEDIA

Japanese company Eisai is expanding its geographical and patient
reach by opening a new regional representative office in Dubai today.

The Eisai EMEA (Europe, Middle East and Africa) Dubai branch
office, located in Dubai Healthcare City (DHCC), marks the increased
global presence of the company and supports Eisai's vision to secure
patient access to innovative and novel treatments not previously
available to them. This forms part of the company's new
organisational structure as set out in its mid-term strategic plan
HAYABUSA.

"Eisai's entry into the Middle East and Africa region enforces our
wider plan of increasing access to medicines based on a strategy of
affordability, availability, adoption and architecture," points out
the new EMEA Regional Director, Ayman ElDeeb. "This expansion is an
opportunity to make our currently marketed and pipeline products
available, as well as to explore in-licensing of products which may
match specific patient needs in the region."

Eisai has already launched Methycobal(R) (mecobalamin), a
treatment for peripheral neuropathy, in Saudi Arabia, the United Arab
Emirates and other countries in the Middle East. The company now
plans to register and introduce selected oncology and neurology
products to the region, including the new metastatic breast cancer
treatment Halaven(R) (eribulin) and a novel agent for the treatment
of epilepsy. This move further supports Eisai's human health care
(hhc) mission to address unmet medical needs and contribute to the
health and well-being of people worldwide.

Eisai's commitment to establish a strong presence in the Middle
East, North and South Africa is further seen by the establishment of
a new EMEA business headquarters based in Hatfield, UK. The GBP100m
facility, which opened in 2009, initially focused solely in Europe,
but now supports the company's growing EMEA business. Eisai Co., Ltd.
was established in 1941 in Tokyo, Japan where our global headquarters
are located. In 2011, Eisai hit a major milestone by celebrating its
70th anniversary.

Eisai is proud to be working with DHCC on the expansion into the
Middle East and parts of Africa. DHCC was launch in 2002 and it
combines the leading expertise of medical institutions and
pre-eminent healthcare providers to deliver the A to Z of medical
services.

Notes to Editors

About Eisai

Eisai is one of the world's leading R&D-based pharmaceutical
companies and has defined its corporate mission as "giving first
thought to patients and their families and to increasing the benefits
health care provides," which we call human health care (hhc). Eisai
recently expanded their UK Hatfield facility which now supports the
company's growing European, Middle Eastern and African (EMEA)
business.

Eisai concentrates its R&D activities in three key areas:

- Neuroscience, including: Alzheimer's disease, multiple 
sclerosis,
          neuropathic pain, epilepsy, depression
        - Oncology including: anticancer therapies; tumour 
regression, tumour
          suppression, antibodies, etc and supportive cancer 
therapies; pain relief, nausea
        - Vascular/Immunological reaction including: acute coronary 
syndrome,
          atherothrombotic disease, rheumatoid arthritis, psoriasis, 
Crohn's disease

With operations in the U.S., Asia, Europe and its domestic home
market of Japan, Eisai employs more than 11,000 people worldwide. In
Europe, Eisai undertakes sales and marketing operations in over 20
markets, including the United Kingdom, France, Germany, Italy, Spain,
Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway,
Portugal, Iceland, Czech Republic, Slovakia, the Netherlands, and
Belgium.

For further information please visit our web site
http://www.eisai.com

About Eisai's Commitment to Neglected Tropical Diseases

Alongside other leading pharmaceutical companies, Eisai signed a
declaration earlier this year in London with the Bill & Melinda Gates
Foundation, the WHO, the US and UK governments, the World Bank and
governments from neglected tropical disease (NTD) endemic countries
to make a coordinated effort to eliminate 10 NTDs by 2020. Eisai is
the only Japanese company to join the 'London Declaration'.

Eisai has also recently announced that it has discovered a
potential treatment for Chagas disease and the UK Wellcome Trust is
funding its development

About Eisai's Commitment to Improving Global Access to Medicines

Today, it is estimated that some 2.7 billion* people around the
world live on US$ 2 or less per day. Most of these 2.7 billion people
do not have access to essential health care and treatment despite the
availability of effective medicines. This is an international
challenge that needs to be solved through collaborations among
governments, international organisations such as the WHO,
non-governmental organisations and pharmaceutical companies.

In line with its human health care (hhc) mission, Eisai is
committed to improving global access to medicines over the
medium-to-long term through partnership strategies that involve
working with governments, international organisations, private
entities and non-profit organisations. Specifically, the company has
developed and is implementing a five-target approach to improve
access to medicines worldwide. The five key components are: product
creations, strategic solutions, capacity building, quality
innovation, and long-term investment.

For further information on Eisai's Access to Medicines
initiatives, please visit the Access to Medicines page on the Eisai
Global website: http://www.eisai.com/company/atm/index.html

* Source: World Bank (2005)

About Eisai's plan HAYABUSA

HAYABUSA is the name of Eisai's medium-term strategic plan,
embarked on from April 2011. It aims for sales of 800 billion yen or
more and operating profit of 200 billion yen or more by the end of
the fiscal year of 2015. In the HAYABUSA plan, Eisai will seek to
establish a presence in each of the world's top 20 pharmaceutical
markets in an effort to achieve its objective of making contributions
to more than 500 million patients worldwide.

Eisai in Oncology

Eisai is dedicated to discovering, developing and producing
innovative oncology therapies that can make a difference and impact
the lives of patients and their families. This passion for people is
part of Eisai's human health care (hhc) mission, which strives for
better understanding of the needs of patients and their families to
increase the benefits health care provides. Our commitment to
meaningful progress in oncology research, built on scientific
expertise, is supported by a global capability to conduct discovery
and preclinical research, and develop small molecules, therapeutic
vaccines, and biologic and supportive care agents for cancer across
multiple indications.

About Eisai in Epilepsy

Eisai is committed to developing and delivering highly beneficial
new treatments to help improve the lives of people with epilepsy. The
development of anti-epileptic drugs (AEDs) is a major strategic area
for Eisai in the EMEA market. In the European Union and Switzerland,
Eisai currently has three marketed treatments including:

- Zonegran(R) (zonisamide) as adjunctive therapy in adult 
patients with
          partial-onset seizures, with or without secondary 
generalisation
        - Zebinix(R) (eslicarbazepine acetate) as adjunctive therapy 
in adult patients
          with partial-onset seizures, with or without secondary 
generalization
        - Inovelon(R) (rufinamide) for the adjunctive treatment of 
seizures associated
          with Lennox-Gastaut Syndrome in patients >4 years

Rückfragehinweis:
For local media information or to attend the Dubai office opening
ceremony on 18 April 2012, please contact:

Khulood Buaisha, Telephone: +971-4-324-5555 / Direct line
+971-4-3622713,
Email: [email protected]; Media Enquiries, Eisai Europe Ltd,
Charlotte Andrews / Cressida Robson, +44-(0)7947-231513 /
+44-(0)790-831-4155,[email protected] /
[email protected];

Tonic Life Communications, Benjamyn Tan / Leah Peyton,
+44-(0)207-798-9262
/ +44-(0)7788-191434,
[email protected] / [email protected]

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | PRN

print